Krystal Biotech Inc. (KRYS) Dividend Safety Gauge & 10-Year DRIP Compounder

The per the Roarable RQD rating, KRYS scores 72 out of 100, grading B, with the verdict "Roarable Buy — Good Risk/Reward." The five pillars are:

• Fundamental Cash Engine: 17 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 16.5% and an FCF yield of 1.97%. For an investor, this is the strongest evidence that the business converts capital into returns, though the low FCF yield means the market is paying a high price for each dollar of free cash flow.
• Whale 13F Flow: 10 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. The moderate score suggests institutional support is present but not dominant; no 13F detail is provided beyond the score.
• Insider Conviction: 12 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. A mid-range score indicates insider signals are neither a strong endorsement nor a warning.
• Macro Regime Fit: 15 / 20. Per the Roarable RQD rating, this pillar reflects beta of 0.91 and sector sensitivity. A beta below 1 implies the stock has historically moved less than the market, a defensive trait that benefits investors in volatile regimes but may lag in strong rallies.
• Forensic Balance Sheet: 18 / 20. Per the Roarable RQD rating, this pillar reflects Altman Z of 26, Piotroski F of 8/9, and Debt/Equity of 0.04. This is the strongest pillar and indicates low financial distress risk.

Valuation tradeoff: per the market data, the stock trades at a trailing P/E of 46.9 and an EV/EBITDA of 53.4, which the Roarable RQD rating does not separately penalize within its five pillars. An investor should weigh the strong forensic and cash-generation scores against the premium multiples and the 1.97% FCF yield when evaluating the stock today. This is an analytical framing, not personalized advice.

Per the SEC financials, revenue rose from $50.7M in FY 2023 to $389.1M in FY 2025, and operating income moved from $-109.6M to $161.3M over the same span. Per the market data, the operating margin is 41.5% and the net margin is 52.6%, with ROIC at 16.5%. Per the Roarable RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 8/9. Per the SEC financials, debt fell from $1236.3M in FY 2023 to $51.4M in FY 2025, and the RQD rating reports Debt/Equity of 0.04. Gross margin is reported as 0% in the market data and should be treated as unreliable without further context.

• What are the company's specific products, approved indications, and revenue concentration, given the profile provides only sector and industry labels?
• What drove the move from $50.7M revenue in FY 2023 to $389.1M in FY 2025, and is that growth sustainable?
• Why is gross margin reported as 0%, and what is the true cost structure?
• Which institutions hold KRYS, and how have their positions changed over time?
• How do analysts value the stock relative to a 46.9 trailing P/E and 53.4 EV/EBITDA?